Navigation Links
QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
Date:2/7/2008

MELBOURNE, Florida, February 7 /PRNewswire/ -- QuoNova LLC, which is 88.7% owned by XL TechGroup, Inc. (AIM: XLT), has generated preliminary in-vitro data indicating high efficacy of selected Quorum Sensing Blockers ("QSB") in inhibiting biofilm formation by MRSA (methicillin-resistant Staphylococcus aureus) strains and fungal organisms such as Candida sp.

QuoNova's business strategy is to develop and commercialize its proprietary QSB "disruptive technology" platform to address unmet needs in several multi-billion dollar markets including therapeutics, medical devices, consumer care, agriculture and several industrial applications.

QuoNova has optimized its proprietary QSB technology to obtain small molecules with a broad activity profile that are effective against multiple pathogenic Gram-positive and Gram-negative bacterial strains as well as fungi. These promising results, which are the subject of continuing research, further underscore the potential of QuoNova's QSB in combating the detrimental effects of biofilms, especially in clinical environments, where mixed microbial communities predominate. MRSA bacteria (hospital and community acquired) cause increasing healthcare problems due to their resistance against most conventional antibiotic therapies.

Importantly, QuoNova's QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated the efficacy of its QSB technology in a predictive animal model where QSBs significantly reduced the ability of clinically relevant bacteria to colonize secondary burn wounds. In addition, a marked synergy with Silver Sulfadiazine (SSD), a commonly used antibacterial preparation, was observed.

"These are promising results which significantly broaden the reach of our platform and further illustrate the impact of QuoNova's QSB technology in combating the
'/>"/>

SOURCE QuoNova LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Egenix Licenses Harvard Anti-Cancer Platform
2. Nikon Instruments New NIS-Elements C Delivers Comprehensive Confocal and Widefield Imaging Capabilities in Single Unifying Software Platform
3. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
4. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
5. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
6. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
7. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
8. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... YORK , 27. März 2015 /PRNewswire/ ... Prize in Biomedical Science für seine bahnbrechende ... Proteine zwischen Zellkompartimenten transportiert werden, sowie für ... Zellen zur Reaktion auf Stress nutzen, der ... Dr. Walter ist Professor für Biochemie an ...
(Date:3/27/2015)... Working in collaboration with the National Amyloidosis Centre at ... Richmond Pharmacology is the first centre worldwide to dose a ... RNAi therapeutic being developed for the treatment of transthyretin-mediated amyloidosis ... Read press release ClinicalTrials.gov ... University of London , Richmond Pharmacology is ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
Breaking Biology Technology:Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7
... , SADDLE RIVER, N.J., July 29 PDI, ... sales and marketing support to U.S. pharmaceutical companies, today announced that ... August 5, 2009 after the market close. , , ... at 4:30 p.m. Eastern time on August 5, 2009 to discuss ...
... RICHMOND, Calif., July 29 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments. , , For the second ... of $4.5 million, or $0.11 per share, compared to a consolidated ... same period in 2008. As of June 30, 2009, the company ...
... , , , ... Corporation (Nasdaq: VRNM ) today announced that its ... Biofuels, and plan to relocate its corporate headquarters to Florida. ... the nation,s first commercial-scale cellulosic ethanol facilities, located in Highlands ...
Cached Biology Technology:PDI, Inc. to Hold Second Quarter 2009 Financial Results Conference Call on Wednesday, August 5, 2009 2Sangamo BioSciences Reports Second Quarter 2009 Financial Results 2Sangamo BioSciences Reports Second Quarter 2009 Financial Results 3Sangamo BioSciences Reports Second Quarter 2009 Financial Results 4Sangamo BioSciences Reports Second Quarter 2009 Financial Results 5Sangamo BioSciences Reports Second Quarter 2009 Financial Results 6Sangamo BioSciences Reports Second Quarter 2009 Financial Results 7BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 2BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 3BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 4
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... scans to measure blood flow in the lungs of people ... are most at risk of emphysema before the disease damages ... University of Iowa study. The study found that smokers ... normal lung function, have very different blood flow patterns in ...
... Chronix Biomedical today announced publication of a study ... tests to predict clinical status and monitor disease activity ... Chronix Biomedical uses proprietary technology to identify disease-specific genetic ... into the bloodstream by damaged and dying cells. ...
... 2010) -- A scientist at Barrow Neurological Institute in Phoenix ... Association (MDA) to continue his groundbreaking work in the disease ... part of MDA,s ongoing commitment to fund neuromuscular research that ... and related diseases. Including this funding, the MDA has ...
Cached Biology News:New test could identify smokers at risk of emphysema 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 3Barrow scientist receives $450K MDA grant 2
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... Kit is a simple high performance method ... Removes detergents without significant dilution of protein ... on the Detergent-OUT Spin column and collect ... column is suitable for removing detergents from ...
... The wide and long ... of Polaroid gel documentation systems. ... holds the camera in place ... that allows photography on the ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
Biology Products: